VVM
LENZ

Versant Venture Management’s LENZ Therapeutics LENZ Stock Holding History

Versant Venture Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.1M Hold
2,656,888
– – 9.28% 4
2026
Q1 		$24.3M Hold
2,656,888
– – 17.19% 3
2025
Q4 		$42.5M Hold
2,656,888
– – 28.14% 2
2025
Q3 		$124M Buy
+2,656,888
New +$97.7M 58.25% 1

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return

Versant Venture Management's LENZ Position: Q2 2026 in Review

Versant Venture Management held its LENZ Therapeutics (LENZ) position steady in Q2 2026 at 2,656,888 shares worth $15.1M. The position accounts for 9.28% of the portfolio, ranked #4.

Versant Venture Management first reported a position in LENZ in Q3 2025 and has held it in 4 quarters since. The position peaked at $124M in Q3 2025. 144 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Versant Venture Management held 2,656,888 shares of LENZ Therapeutics worth $15.1M as of Q2 2026.
  • Versant Venture Management left its LENZ Therapeutics share count unchanged in Q2 2026.
  • LENZ Therapeutics made up 9.28% of Versant Venture Management's portfolio in Q2 2026, its #4 holding.
  • Versant Venture Management first reported a position in LENZ Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Versant Venture Management's LENZ Therapeutics position peaked at $124M in Q3 2025.
  • 144 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Versant Venture Management's 13F filing for Q2 2026, filed 12 Aug 2026.